Safety and efficacy results from A phase 1b study of R289, a dual irak 1/4 inhibitor, in patients with Relapsed/Refractory (R/R) lower risk myelodysplastic syndrome (LR-MDS).
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Guillermo Garcia-Manero, Yazan Madanat, Mikkael Sekeres, Hetty Carraway, Mike Cusnir, James McCloskey, Kiran Naqvi, Gary Schiller, Frank Hsu, Toufigh Gordi, Lisa Rojkjaer, Lewis R Silverman
Institutions: The University of Texas MD Anderson Cancer Center, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, University of Miami, Sylvester Comprehensive Cancer Center, Cleveland Clinic, Mount Sinai Medical Center, Hackensack University Medical Center, University of California, Irvine, University of California, Los Angeles, Rigel (United States), Icahn School of Medicine at Mount Sinai
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7108460896
Cites:
Cited by:
Related to: